An open label positron emission tomography [PET] study in healthy male subjects to investigate brain dopamine D3 occupancy kinetics, pharmacokinetics and safety of single oral doses of GSK598809, using [11C]-(+)-PHNO as PET ligand

Trial Profile

An open label positron emission tomography [PET] study in healthy male subjects to investigate brain dopamine D3 occupancy kinetics, pharmacokinetics and safety of single oral doses of GSK598809, using [11C]-(+)-PHNO as PET ligand

Completed
Phase of Trial: Phase I

Latest Information Update: 20 May 2009

At a glance

  • Drugs GSK 598809 (Primary)
  • Indications Drug abuse; Eating disorders; Smoking withdrawal
  • Focus Pharmacokinetics
  • Most Recent Events

    • 11 May 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top